Paul F. Engstrom
YOU?
Author Swipe
Supplementary Figures 1-2, Tables 1-5 from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Supplementary Figures 1-2, Tables 1-5. Supplemental Figure 1. Flow diagrams showing the design and collection of the reference set. Supplemental Figure 2. Clustering of the 90 analytes across all 505 subjects. Supplemental Table 1: Subject…
Participant and Clinical Information Form from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Participant and Clinical Information Form. Study forms used to obtain subject and clinical information.
Supplemental Figure and Table Legend from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Supplemental Figure and Table Legend
Participant and Clinical Information Form from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Participant and Clinical Information Form. Study forms used to obtain subject and clinical information.
Data from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Researc…
Supplementary Figures 1-2, Tables 1-5 from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Supplementary Figures 1-2, Tables 1-5. Supplemental Figure 1. Flow diagrams showing the design and collection of the reference set. Supplemental Figure 2. Clustering of the 90 analytes across all 505 subjects. Supplemental Table 1: Subject…
Data from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Researc…
Supplemental Figure and Table Legend from Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Open
Supplemental Figure and Table Legend
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials Open
Neuroendocrine tumors (NETs) have historically been subcategorized according to histologic features and the site of anatomic origin. Here, we characterize the genomic alterations in patients enrolled in three phase 3 clinical trials of NET…
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology Open
The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although cer…
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology Open
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, and survi…
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018 Open
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relie…
E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors Open
Lessons Learned Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer. Landmark analyses can also be complicated by e…
NCCN Guidelines Insights: Colon Cancer, Version 2.2018 Open
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN …
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology Open
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy…
Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer Open
This study is the largest analysis to date of TNBC in the context of racial/ethnic identity and BBD as risk factors. The study found that AA identity persisted as a significant risk factor for TNBC. This finding suggests that AA identity i…